These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10558042)

  • 1. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center.
    Mole L; Ockrim K; Holodniy M
    Pharmacoeconomics; 1999 Sep; 16(3):307-15. PubMed ID: 10558042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy.
    Baum SE; Morris JT; Gibbons RV; Cooper R
    Mil Med; 1999 Sep; 164(9):609-12. PubMed ID: 10495628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
    Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
    Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
    Llibre-Codina JM; Casado-Gómez MA; Sánchez-de la Rosa R; Pérez-Elías MJ; Santos-González J; Miralles-Alvarez C; Martínez-Chamorro E; Domingo-Pedrol P; Alvarez-García ML; Moreno-Guillén S
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):98-107. PubMed ID: 17288907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
    Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
    Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient, Outpatient, and Pharmacy Costs in Patients With and Without HIV in the US Veteran's Affairs Administration System.
    Sutton S; Magagnoli J; Cummings T; Hardin J; Edun B
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219855377. PubMed ID: 31213120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual nucleoside analogue treatment in the era of highly active antiretroviral therapy (HAART): a single-centre cross-sectional survey.
    Manfredi R; Calza L; Chiodo F
    J Antimicrob Chemother; 2001 Aug; 48(2):299-302. PubMed ID: 11481306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of late entry into medical care for patients with HIV infection.
    Fleishman JA; Yehia BR; Moore RD; Gebo KA;
    Med Care; 2010 Dec; 48(12):1071-9. PubMed ID: 21063228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary costs of HIV healthcare in the HAART era.
    Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
    AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.